Table 2.
Summary of outcomes for each agent
| Type of intervention | Outcomes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TFG < 3 | STR | LVEF | MACEs | AEs | |||||||
| Events | Total | Events | Total | Mean | SD | Total | Events | Total | Events | Total | |
| Adenosine | 82 | 978 | 538 | 931 | 48.80 | 11.72 | 502 | 115 | 959 | 258 | 796 |
| Anisodamine | 18 | 184 | 140 | 184 | 58.78 | 10.31 | 208 | 11 | 208 | 29 | 158 |
| Diltiazem | 20 | 88 | 43 | 88 | 54.21 | 12.33 | 88 | 12 | 88 | 19 | 54 |
| Nicorandil | 7 | 207 | 33 | 57 | 55.18 | 11.75 | 112 | 20 | 148 | – | – |
| Nitroprusside | 57 | 551 | 191 | 317 | 51.46 | 12.44 | 199 | 26 | 363 | 50 | 317 |
| Urapidil | 1 | 27 | 25 | 27 | 54.32 | 6.65 | 49 | 0 | 27 | 4 | 27 |
| Verapamil | 26 | 181 | 34 | 79 | 52.56 | 12.48 | 181 | 18 | 151 | 3 | 30 |
| Control | 263 | 1693 | 608 | 1219 | 50.57 | 10.88 | 943 | 228 | 1478 | 87 | 1008 |
TFG, TIMI flow grade; STR, ST-segment resolution; LVEF, left ventricular ejection fraction; MACEs, major adverse cardiovascular events; AEs, adverse events